Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

Merck,Logo,,Sign,At,Merck,Research,Laboratories,In,Silicon,Valley.

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

In the MK-8591A-052 trial, the suppression was on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) and baseline antiretroviral therapy (bART) in trial MK-8591A-051.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.